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1. Introduction  
Hepatocellular carcinoma (HCC) is one of the most common cancers in the world, 
showing a rapid progressive clinical course, poor response to pharmacological treatment 
and a severe prognosis (Colombo, 2003; Sherlock & Dooley, 2002). HCC generally 
develops from chronic liver injury, which leads to inflammation, hepatocyte regeneration, 
liver matrix remodeling, fibrosis, and finally, cirrhosis. The main risk factors for HCC are 
hepatitis B (HBV) or C virus (HCV) infection, alcohol-induced liver disease (ALD), non-
alcoholic fatty liver disease (NAFLD), primary biliary cirrhosis and exposure to 
environmental carcinogens (particularly aflatoxin), and genetic metabolic diseases. 
(Chuang et al., 2009; Di Bisceglie, 1995; Kato et al, 1994; Malaguarnera et al., 2006; 
Malaguarnera et al., 2009; Seitz & Becker, 2007;  Takano et al., 1995). Obesity has also been 
identified as an independent risk factor for developing HCC in patients with alcoholic or 
cryptogenic cirrhosis (Nair et al, 2002). Actually, HCV-related cirrhosis is considered the 
major risk factor since many HCV chronically infected patients remain asymptomatic for a 
long period, with liver cirrhosis developing after approximately 30 years (Yano et al., 
1996; Poynard et al., 1997). The lack of predictive markers that makes unforeseeable the 
insurgence of liver cirrhosis in chronic HCV patients may also contribute to HCC late 
diagnosis, progression and poor prognosis. Currently, alpha-fetoprotein (AFP) is the most 
common marker for early malignancy used in clinical practice, in combination with 
hepatic echography, to detect HCC in patients suffering from cirrhosis. Nevertheless, 
most episodes of AFP elevation were transient and closely correlated with the presence of 
bridging hepatic necrosis, without subsequent development of HCC (Liaw et al., 1986). 
Since an early diagnosis of HCC is extremely important in improving the survival of 
patients, the identification of new and more reliable biological markers of HCC 
insurgence, recurrence and metastasis is essential for the proper management of this 
malignancy. Once hepatic cancer develops, one of the main reasons for the high mortality 
rate in patients with HCC is the lack of effective treatment options, especially for those 
with advanced disease. Although surgery and percutaneous ablation can achieve long-
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term control in some patients with early HCC, recurrence rates are high, approximately 
50% at 3 years (Mulcahy, 2005). Furthermore, due to the asymptomatic nature of early 
HCC, lack of awareness and poorly defined screening strategies, approximately 80% of 
patients present with advanced or unresectable disease (Thomas & Abbruzzese, 2005). 
These patients generally have a very poor prognosis and treatments, such as transarterial 
chemoembolization, intra-arterial or systemic chemotherapy, radiotherapy, 
immunotherapy or hormonal therapy, are mainly used as palliative, with a 5-year relative 
survival rate of only 7% (Bosch et al., 2004).  
The lack of effective and well-tolerated treatments for advanced HCC highlights the need 
for innovative approaches for diagnosis, prognosis and therapy for hepatic cancer. In this 
context, multiparametric platforms allowing simultaneous detection of multiple 
serological and immunohistochemical markers for HCC insurgence, recurrence and 
metastasis would represent a high-performance technological tools useful not only for 
diagnosis and prognosis, but also for improving the clinical management of HCC patients, 
allowing us, in the near future, to design therapies adapted to the aggressiveness of each 
individual tumor. 
Starting from this background, in this chapter will be collected some of the data existing in 
literature on the main serological and immunohistochemical biomarkers for HCC diagnosis, 
prognosis and target therapy, also focusing on new molecules which might be attractive 
candidates for improvement of the diagnostic/therapeutic approaches. In particular will be 
covered the following topics : 1) Some new candidates recently proposed as potential 
biological markers of HCC insurgence, recurrence and metastasis, that could be useful for 
early diagnosis of this malignancy and improve patient’s prognosis; 2) Some signaling 
pathways which deregulation or constitutive activation have been demonstrated to have a 
role in HCC insurgence and progression and that could be of interest for therapeutic 
perspectives, since targeting them may contribute to prevent tumorigenesis or achieve 
tumor reversion; 3) Molecules over-expressed in late stages of cancer or in the metastatic 
diseases that should be considered a good targets for therapy and drug delivery. 
2. Biological markers useful for early diagnosis of HCC insurgence, 
recurrence and metastasis 
Currently, the diagnosis of HCC is mainly based on the atypical histopathology of bioptic 
liver tissues, combined with the laboratory screening including the index of hepatic damage 
(alanine aminotransferase and aspartate aminotransferase), the index of hepatic synthesis 
(albumin, prothrombin time, bilirubin), the index of cholestasis (alkaline phosphatase and 
gamma-glutamyl transpeptidase), and finally, tumor markers and instrumental analyses, 
including hepatic ultrasonography, computed tomography, nuclear magnetic resonance. 
Some of the tumor markers for HCC diagnosis, such as alpha-fetoprotein (AFP), lens 
culinaris agglutinin-reactive AFP (AFP-L3) and des-Ǆ-carboxyprothrombin (DCP) have now 
been incorporated into HCC staging classification (Marrero et al., 2010) and are routinely 
taken into account for the screening for early malignancy (Table 1). Other biomarkers, 
including some growth factors, such as Vascular Endothelial Growth Factor (VEGF), 
Transforming Growth Factor ǃ1 (TGF-ǃ1), Hepatocyte Growth Factor EGF), Epidermal 
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Growth Factor receptor (EGFR), and numerous other molecules (Table 1), are used as 
diagnostic/prognostic aid for HCC and for staging (Malaguarnera et al., 2010; Mann et al., 
2007; Qin & Tang, 2004). Nevertheless, each existing marker alone is poorly specific to 
predict the disease and most markers are not related to each other. Currently the absolute 
positive and negative serological and/or immunohistochemical markers for HCC are still 
lacking, and even those selected for high sensitivity and specificity do not exhibit an 
universal diagnostic/prognostic value. Therefore, in the last years, a great number of 
studies has been dedicated to the discovery and validation of more specific biomarkers for 
HCC, driven by the idea that the simultaneous screening for multiple markers should 
greatly reduce errors from false-negative results, which significantly contribute to an 
incorrect diagnosis. 
2.1 Main markers used for the screening for early malignancy  
Alpha-fetoprotein (AFP) is a 70 kDa glycoprotein that is physiologically synthesized by 
the embryonic liver cells of the yolk sac and fetal intestinal tract. The AFP is expressed in 
hepatocytes and endodermal cells of the yolk sac during fetal life and its expression is 
reduced after birth, with very low levels in adults. The AFP levels rise in hepatocyte 
regeneration, hepatocarcinogenesis, and embryonic carcinomas. Its biological function in 
embryo- and carcinogenesis and in adult organisms is still not well identified, but, due to 
its structural similarity with albumin, a function as a carrier for several ligands, 
including bilirubin, steroids, fatty acids and various drugs has been proposed 
(Mizejewski, 2002; Terentiev & Moldogazieva, 2006). Recognized as a tumor-associated 
fetal protein, AFP has long been considered the 'gold-standard' among tumor markers, 
and, it has been purified, characterized, cloned and sequenced for use in the clinical 
diagnostic. It is principally used: i) for the screening and diagnosis of hepatocarcinoma 
in patients at risk of developing HCC, in combination with hepatic ultrasonography; ii) 
as a marker of tumor progression in HCC patients with high levels of AFP; iii) for 
monitoring the response to treatment during the follow-up of HCC patients, with a 
prognostic value; iv) in HCC staging. 
Lens culinaris agglutinin-reactive AFP (AFP-L3) is one of the AFP isoform which exhibits an 
elevated affinity for Lens culinaris agglutinin (LCA). This AFP isoform, that has ǂ1→6 fucose 
residues on N-acetylglucosamine at reducing end, seems to be exclusively expressed by 
cancer cells, and is considered  a more specific marker for HCC (Oka et al., 2001; Sato et al., 
1993). AFP-L3 should be used as a supplemental test in patients with elevated total AFP. It 
has been reported as a potential indicator of a poor prognosis, since increasing AFP-L3 
levels seem to correlate with progression from moderately differentiated to poorly 
differentiated tumors (Miyaaki et al., 2007). 
Des-c-carboxy prothrombin (DCP) or prothrombin induced by vitamin K absence (PIVKA) 
is an abnormal prothrombin derived by an acquired defect in the post-translational 
carboxylation of the prothrombin precursor in HCC cells (Ono et al., 1990). DCP derives by 
a reduced activity of gamma-glutamyl carboxylase, highly expressed in the liver; this 
reduced activity is attributed to defective gene expression in HCC patients (Grizzi et al., 
2007). DCP is a HCC marker more specific than AFP since other liver diseases are not 
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associated to an increase of DCP serum levels. Apart its diagnostic significance, increased 
DCP levels may also have a prognostic value, being often related to early portal vein 
invasion and metastatization by cancer cells. 
2.2 Some growth factors used as diagnostic/prognostic aid  
Vascular Endothelial Growth Factor (VEGF), plays an crucial role in angiogenesis and is 
highly expressed in various human cancers (Brown et al., 1993; Mattern et al., 1996; Toi et 
al., 1994), including HCC (Mise et al., 1996; Suzuki et al., 1996). Specifically,  VEGF levels 
are higher in HCC patients than in patients suffering from chronic hepatitis, and its 
expression is more elevated in advanced HCC as compared to early HCC.  High serum 
VEGF levels are associated with tumors with portal vein emboli, poor-encapsulated 
tumors, microscopic vein invasion, and recurrence in HCC patients (Li et al., 1999). It is 
considered as a possible marker for predicting invasion and metastatization of HCC, and 
in general, of tumor aggressiveness. 
Transforming Growth Factor ǃ1 (TGF-ǃ1), is a polypeptide member of the transforming 
growth factor beta superfamily of cytokines. It is an important mediator of control of liver 
cell proliferation and replication. In normal liver tissues, TGF-ǃ1 is produced by non-
parenchymal cells (Kupffer cells, storing cells, and endothelial cells), but not by hepatocytes. 
Conversely, transcription of TGF-ǃ1 gene is activated in human HCC tissues and is higher 
in patients with advancing histological aggressiveness (Ito et al., 1990). Moreover, TGF-ǃ1 
serum levels are reported to be increased in HCC patients (Grizzi et al., 2007). TGF-ǃ1 has 
been proposed as a possible prognostic factor for reduced survival in patients with HCC 
(Mann et al., 2007; Okumoto et al., 2004; Tsai et al., 1997) 
Hepatocyte growth factor (HGF) is a cytokine with a wide range of effects, including liver 
regeneration for  protection and/or repair of different organs, including kidney, lung, and 
cardiovascular system (Birchmeier et al., 1998). It promotes proliferation in normal 
hepatocyte and in hepatocellular carcinoma cells (Breuhan et al., 2006) through expression 
of its high-affinity tyrosine kinase receptor (Met/HGF-R). HGF is detected in the serum 
from patients suffering from hepatic chronic disease and its serum values seems to be 
correlated with a worsening of liver disease (Breuhan et al., 2006). Increased HGF serum 
levels in cirrhotic patients is an indicator of HCC development (Yamagamim et al., 2002). It 
is considered a prognostic marker since elevated HGF serum levels, are predictive of HCC 
recurrence and metastasis after hepatic resection (Wu et al., 2006). 
Epidermal growth factor receptor (EGFR) is a member of the ErbB family of receptors, a 
subfamily of four closely related receptor tyrosine kinases, EGFR (ErbB-1), HER2/c-neu 
(ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). These receptors bind ligands of the EGF family, 
including EGF, TGF-ǂ and heparin-binding EGF. EGFR has been found to be overexpressed 
in poorly differentiated HCC and primarily in patients with early tumor recurrence (Daveau 
et al., 2003; Ito  et al., 2001) EGFR  tissue overexpression is also correlated with high 
proliferating activity, advanced stage, the presence of intrahepatic metastasis and poor 
disease-free survival following resection (Ito  et al., 2001). EGFR strongly reflects the 
biological aggressiveness of HCC and might be considered a possible prognostic factor of 
reduced survival of HCC patients. 
www.intechopen.com
New Molecular Biomarkers Candidates for the Development of Multiparametric  
Platforms for Hepatocellular Carcinoma Diagnosis, Prognosis and Personalised Therapy 
 
77 
HCC biomarker Biological 
material mainly 
analyzed 
Main use/s References 
Alpha-fetoprotein 
(AFP) 
Serum 
Early diagnosis; HCC staging; 
monitoring the response to 
treatment during the follow-
up of patients with HCC
Terentiev & Moldogazieva, 
2006; Mizejewski, 2002; 
Malaguarnera et al., 2010; 
Marrero et al., 2010 
Lens culinaris 
agglutinin-reactive 
AFP (AFP-L3) 
Serum 
Early diagnosis and prognosis; 
progression from moderately 
differentiated to poorly 
differentiated tumors
Oka et al., 2001; Sato et al., 
1993; Malaguarnera et al., 
2010; Marrero et al., 2004 
Des-c-carboxy 
prothrombin (DCP) 
Serum 
Early diagnosis and prognosis 
(more specific than AFP); 
related to early portal vein 
invasion and metastasis
Grizzi et al., 2007; 
Malaguarnera et al., 2010; 
Marrero et al., 2004 
Golgi protein-73 Serum HCC early diagnosis Malaguarnera et al., 2010  
Squamous cell 
carcinoma antigen 
(SCCA) 
Tissue/Serum 
Early diagnosis; detection of 
micro-metastasis in tissues; 
large-scale screening of serum 
in patients at risk
Malaguarnera et al., 2010 
Glypican-3 Tissue/Serum 
HCC early diagnosis; useful 
for discriminating malignant 
from benign hepatic lesions
Malaguarnera et al., 2010 
Vascular Endothelial 
Growth Factor (VEGF)
Tissue/Serum 
HCC prognosis; predictive of 
invasion and metastatization 
of HCC cells  
Suzuki et al., 1996; Mise et 
al., 1996; Li et al., 1999; Qin 
&Tang, 2004; Mann et al., 
2007; Malaguarnera et al., 
2010  
Transforming Growth 
Factor ǃ1 (TGF-ǃ1) Tissue/Serum 
HCC progression; prognostic 
factor for reduced survival in 
patients with HCC 
Ito et al., 1990; Grizzi et al., 
2007; Mann et al., 2007; 
Okumoto et al., 2004; Tsai et 
al., 1997 
Hepatocyte Growth 
Factor (HGF) 
Serum 
HCC prognosis; predictive of 
HCC recurrence and 
metastasis after hepatic 
resection 
Breuhan et al., 2006; 
Yamagamim et al., 2002; Wu 
et al., 2006; Malaguarnera et 
al., 2010 
Epidermal Growth 
Factor Receptor 
(EGFR) 
Tissue 
HCC prognosis; predictive of 
reduced survival of HCC 
patients 
Daveau et al., 2003; Ito  et 
al., 2001; Mann et al., 2007 
p53 antibodies Serum 
HCC prognosis (poor 
differentiation); associated 
with a poor prognosis of HCC 
patients 
Malaguarnera et al., 2010 
Survivine Tissue 
HCC prognosis; poor 
prognosis following resection 
of HCC; associated with 
reduced disease-free survival.
Fields et al., 2004;  Mann et 
al., 2007 
Nerve Growth Factor 
(NGF) and its high-
affinity receptor 
trkANGF 
Tissue/Serum 
HCC prognosis and 
progression; predictive of 
progression of liver fibrosis 
towards HCC 
Rasi et al, 2007; 
Malaguarnera et al., 2010 
Table 1. List of the main biomarkers useful for HCC diagnosis/prognosis 
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2.3 The Nerve Growth Factor (NGF): A new candidate proposed as potential 
histological/serum marker for HCC diagnosis and prognosis 
In the last years, some new candidates have been proposed as potential biological markers 
of HCC insurgence, recurrence and metastasis, that could be therefore useful for early 
diagnosis of this malignancy and improve patient’s prognosis. In particular we focus on our 
recently published data that suggested an involvement of Nerve Growth Factor (NGF) in 
liver tissue remodelling processes and HCC progression, describing the correlation between 
NGF tissue distribution and serum levels in patients suffering from cirrhosis and/or HCC 
(Rasi et al, 2007).  
NGF is a prototypical member of neurotrophin family essential for survival, differentiation, 
and maintenance of neuronal cells in the central and peripheral nervous system (Levi-
Montalcini, 1987). In recent years, many findings have indicated that NGF could also have a 
role outside the central and peripheral nervous system. In particular, it may be involved in 
lung and skin tissue repair (Micera et al., 2001) as well as in  allergic inflammation and 
fibrosis (Micera  et al., 2003). Increased levels of circulating NGF were observed in several 
autoimmune, chronic inflammatory and fibrotic disorders (Aloe & Tuveri, 1997; Bonini et 
al., 1999). Numerous data also indicate that NGF is involved in tumor growth, invasion and 
metastasis (Bold et al., 1995; Descamps et al., 1998; Djakiew et al., 1991; Koizumi et al., 1998; 
McGregor et al., 1999; Oelmann et al., 1995; Pflug et al., 1992; Revoltella & Butler, 1980; 
Sortino et al., 2000).The NGF effects are mediated by two types of receptor: the high-affinity 
receptor trkANGF, specific for NGF, and the low-affinity glycoprotein receptor p75NTR, also 
binding other neurotrophins (Meakin & Shooter, 1992). Most of the biological activities 
elicited by NGF are mediated by binding to the trkANGF receptor (Sofroniew et al., 2001).  
In the 2007 (Rasi et al., 2007), we provided immunohistochemical evidence that NGF and its 
high-affinity receptor trkANGF are over expressed in patients suffering from HCC (Fig. 1) 
and to a greater extent from HCC with cirrhosis (Fig. 2B, C). Specifically, in HCC tissues 
NGF was detectable in a high number of cells (Table 2), at different levels of intensities 
depending on the patient, but never in normal liver tissue. Interestingly NGF and trkANGF 
were negative in liver specimens from patients with cirrhosis undergoing transplantation 
(Child-C) but without HCC (Fig. 2A), while they were markedly positive in patients with 
cirrhosis that had evolved into HCC, already at early staging (Child- Pugh A, Fig. 2B).  
Transmission electron microscopy, after immunogold labeling, showed that in 
hepatocytes of HCC tissue and, at higher extent, of cirrhotic tissue from the same liver,  
NGF mainly localized on cytoplasmic vesicles, free in the cytoplasm and along 
endoplasmic reticulum (Fig. 3), indicating that it might be actively produced by the 
hepatocytes constituting the cirrhotic/HCC tissues. The evidence that hepatocytes in HCC 
and cirrhotic tissues from the same liver produce NGF and express its receptor suggested 
that NGF may act by both autocrine and paracrine mechanisms, as a messenger molecule 
in the cross-talk between different cell types. Moreover, in sera obtained from patients 
with documented cirrhosis, HCC, or both, circulating NGF levels elevated 25-fold over the 
normal (range 73-520pg/ml, compared to a mean of 20pg/ml in healthy donors) were 
recorded (Fig. 4). These elevated circulating NGF levels, as well as the tissue distribution 
of NGF and its receptor strongly support a correlation between NGF activity and the 
progression of liver fibrosis towards HCC. This open up an interesting perspective for the 
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possible use of NGF, not only as a marker of progression and transformation, but also as 
an attractive target for a new therapeutic approach. 
 
Fig. 1. NGF distribution (red hue) in tissues from healthy donors (A) and from patients 
suffering from HCC (B). Green hue represents the auto-fluorescence used to visualize liver 
tissue morphology. A1 and B1: Images of H&E stained sections close to that used for 
immunohistochemistry. Differently coloured arrows indicate the different cell types (see 
legend). hep: hepatocytes. 
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IF: immunofluorescence labelling; IG: immunogold labelling; nd: not determined. 
*Immunoreaction mainly localized on cytoplasmic vesicles and endoplasmic reticulum. 
**Immunoreaction mainly localized in the portion of cells near the ductal lumen. 
Table 2. Expression of NGF and trkANGF in liver cell types from healthy donors and from 
patients with cirrhosis and HCC. Hep: Hepatocyte; Bec, Biliary epithelial cells; Ec, 
Endothelial cells; Ssc, Spindle-shaped cells; Lymph, Lymphocytes; Kpf, Kupffer cells. 
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Fig. 2. NGF and trkANGF distribution in liver specimens. A: tissues obtained before 
transplantation from patients with cirrhosis but without HCC (Child-Pugh C). B: tissue from 
patient also suffering from cirrhosis with HCC. Red hue  represents the NGF or trkA 
immunostaining; green hue represents the auto-fluorescence used to visualize liver tissue 
morphology. C: Images of H&E stained sections close to that used for 
immunohistochemistry. Differently coloured arrows indicate the different cell types (see 
legend). hep: hepatocytes; bec: biliary epithelial cells; ssc: spindle-shaped cells 
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Fig. 3. NGF distribution in cirrhotic tissue from patient with HCC by immunogold labelling. 
Transmission electron micrographs of hepatocytes showing positive immunogold reaction 
on cytoplasmic vesicles (black arrows), free in the cytoplasm (double pointed arrows) and 
along endoplasmic reticulum (white arrows). hep: hepatocytes; ER: endoplasmic reticulum. 
Scale bars = A: 2μm; B: 100nm. 
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Fig. 4. Bar diagram illustrating the circulating NGF levels, determined by ELISA test , in 
patients with documented cirrhosis/HCC. NGF amounts, reported with regard to the 
etiology, is calculated either as total mean values  SD (all patients examined) or as mean 
values for Child-Pugh class A (score = 5-6), for Child-Pugh class B (score = 7-9) and for 
Child-Pugh class C (score = 10-15). As a control, mean value  SD of circulating NGF levels 
from some healthy individuals is also reported 
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3. Components of signaling pathways involved in HCC insurgence and 
progression as innovative biomarkers for diagnosis, prognosis and drug 
targeting 
In the last years, great attention has been given to some signaling pathways which 
deregulation or constitutive activation have been demonstrated to have a role in cancer 
insurgence and progression. These pathways could be of interest for therapeutic 
perspectives, because targeting them may contribute to prevent tumorigenesis or achieve 
tumor reversion. Drugs directly acting on components of the signaling pathways implicated 
in tumorigenesis have exhibited clinical benefit in patients with various tumor types, 
including colorectal, renal, breast and lung cancers, and more recently, HCC (Whittaker  et 
al., 2010). Thus, deepening of knowledge on the molecular pathways actively involved in 
HCC insurgence and progression could potentially provide new targets for drug delivery 
and therapy, allowing to overcome the poor response to the current therapeutic strategies. 
Moreover, owing the role of these pathways in the carcinogenetic process, crucial molecules 
of this signaling should be validate as new HCC-related biomarkers for the improvement of 
the current diagnostic/prognostic tools. 
3.1 Main signaling pathways implicated in HCC 
During hepatocarcinogenesis, two main pathogenic mechanisms predominate: 1) 
cirrhosis associated with hepatic regeneration after tissue damage caused by hepatitis 
infection, toxins such as alcohol or aflatoxin, or metabolic syndromes such as insulin 
resistance, obesity, type 2 diabetes or dyslipidemia in non-alcoholic steatohepatitis 
(Bugianesi, 2005); 2) mutations occurring in single or multiple oncogenes or tumor 
suppressor genes  (Thorgeirsson & Grisham, 2002; Villanueva et al., 2007; Wang et al., 
2002). These two mechanisms have been related to aberrations in various critical 
molecular signaling pathways that participate to the carcinogenic process. The most 
important of these pathways include the growth factor-mediated angiogenic signaling 
(mainly the VEGF receptor signaling),  the epidermal growth factor receptor (EGFR), the 
insulin growth factor receptor (IGFR), the hepatocyte growth factor receptor HGF/c-
MET signaling, and the platelet-derived growth factor receptor (PDGFR) signaling (Fig. 
5) (Whittaker  et al., 2010).  
Since liver is a highly vascular organ, HCC growth and invasion is highly dependent on 
dysregualtion of angiogenensis (Semela & Dufour, 2004), and targeting molecular 
components of pathway signaling involved in the angiogenetic process are currently the 
main therapeutic strategy exploited for HCC treatment. Actually, targeted drug selectively 
hitting  the VEGF/VEGFR and PDGFR signaling (Sunitinib, Bevacizumab, Cediranib and 
Vatalanib) or the EGF/EGFR and IGFR signaling (Lapatinib, Cetuximab, Erlotinib Gefitinib, 
Everolimus, Sirolimus) (Fig. 5) are under evaluation in phase I-III clinical trials as 
monotherapy or in combination with other chemotherapeutics (see for review, Whittaker  et 
al., 2010). Sorafenib (Nexavar; Bayer HealthCare Pharmaceuticals Inc., Wayne, NJ, USA), a 
potent inhibitor of VEGFR and PDGFR, has been approved for treatment of HCC and is the 
only option of effective systemic treatment currently available for management of the 
advanced malignancy (Llovet  et al., 2008). 
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Fig. 5. Cellular signaling pathways implicated in the pathogenesis of HCC and 
therapeutics targeting molecular components of these pathway, useful for HCC  
treatment. EGF, epidermal growth factor; EGFR, EGF receptor; IGFR, insulin-like  
growth factor receptor; PDGFR, platelet-derived growth factor receptor; WNT, family  
of secreted glycoproteins that act as ligands of the Frizzled receptor;  VEGF, vascular 
endothelial growth factor; VEGFR, VEGF receptor. Details and main function/s of AKT, 
BAD, c-JUN, c-MYC, DSH, ERK 1/2, FOXO, GSK-3ǃ, GBP, MEK 1/2, mTOR, PI3K,  
PTEN, p53,  RAF, RAS, ǃ-catenin, are reported in Table 3. Adapted from Whittaker   
et al., 2010 
Besides the mentioned pathways, directly or indirectly involved in the angiogenic signaling, 
in the last years numerous studies demonstrated that the WNT/ǃ-catenin pathway is 
actively involved in initiation and progression of several kinds of human cancers, including 
HCC (De La et al., 1998; Polakis, 1999; Waltzer & Bienz, 1999) and  growing attention has 
been given to new anti-tumor therapeutic approaches targeting components of this 
signaling pathway (Gonsalves et al., 2011; Luu et al., 2004; Moon et al., 2004). 
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Molecular 
components 
Main Cellular 
signaling 
Main role and function 
AKT  EGF/EGFR,  IGFR  serine/threonine protein kinase involved in 
regulating cell survival 
BAD  EGF/EGFR, IGFR BCL-2-associated death promoter, involved in 
regulating apoptosis 
c-JUN VEGF/VEGFR, 
PDGFR 
in combination with c-FOS, forms the activator 
protein-1 (AP-1) early-response transcription 
factor; involved in cell proliferation and 
apoptosis. 
c-MYC EGF/EGFR , IGFR, 
WNT 
Encodes for a transcription factor that regulates 
the expression of many genes  involved in cell 
proliferation; overexpression of c-MYC is 
associated with carcinogenesis. 
DSH 
(Dishevelled) 
WNT downstream effector of WNT sinaling 
ERK 1/2 VEGF/VEGFR, 
PDGFR 
extracellular signal-regulated kinases 
FOXO (Forkhead 
box subclass O) 
EGF/EGFR , IGFR transcription factor regulating the expression of 
genes involved in cell survival and proliferation 
GSK-3ǃ WNT glycogen synthase kinase-3ǃ, component of ǃ-
catenin destruction complex 
GBP WNT GSK3-binding protein 
MEK 1/2 VEGF/VEGFR, 
PDGFR 
kinases that phosphorylate mitogen-activated 
protein (MAP) kinase (MAPK) 
mTOR EGF/EGFR , IGFR mammalian target of rapamycin, a 
serine/threonine protein kinase that regulates cell 
growth, proliferation, motility, and survival 
PI3K EGF/EGFR , IGFR phosphatidylinositol-3-kinase 
PTEN EGF/EGFR , IGFR phosphatase and tensin homolog that regulates 
cell-survival pathway 
p53 VEGF/VEGFR, 
PDGFR, 
EGF/EGFR, IGFR 
tumor suppressor protein, regulates the cell cycle 
RAF VEGF/VEGFR, 
PDGFR 
MAP kinase kinase kinase (MAP3K); functions in 
the MAPK/ERK signal transduction pathway 
 
RAS  prototypical member of the RAS superfamily of 
proteins; RAS signaling causes cell growth, 
differentiation and survival 
ǃ-catenin WNT integral component of the WNT/ǃ-catenin 
signaling  
Table 3. List of the main molecular component of cellular signaling pathways implicated in 
the pathogenesis of HCC. 
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3.2 Molecular component of the WNT/β-catenin signaling as innovative diagnostic 
biomarkers and therapeutic targets 
Wnts are secreted glycoproteins that act as ligands to stimulate receptor-mediated signal 
transduction pathways in both vertebrates and invertebrates. Activation of Wnt pathways 
can modulate cell proliferation, survival, cell behavior, and cell fate in both embryos and 
adults. Wnt signaling pathway, and its signaling cascade is one of the core signal 
transduction pathway driving tissue morphogenesis during both development and 
progression of human cancers (see for reviews on Wnt: Moon et al., 2004; Nelson et al., 
2004). Wnt signaling also plays a critical role in regulating liver cell proliferation during 
development (Monga et al., 2003; Suksaweang et al., 2004) and in controlling crucial 
functions of the adult liver (Sekine et al., 2006). 
-catenin was originally identified as a protein interacting with the cell adhesion molecule 
E-cadherin (E-cad)  at the cell-cell junction (Ozawa et al., 1989; Vestweber & Kemler, 1984), 
but in the last few years has gained growing interest as one of the most important mediators 
of the Wnt signaling pathway (Moon et al., 2004; Nelson et al., 2004), specifically in respect 
to the role of this pathway in tumorigenesis (Fig. 6). In non normal condition, -catenin 
exists in a cadherin-bound form that regulates adhesion, and the -catenin excess, not 
segregated by E-cad on the cell membrane, is rapidly phosphorylated by glycogen 
synthetase kinase-3ǃ(GSK-3) in the adenomatous polyposis coli (APC)/axin/GSK-3ǃ 
complex (destruction complex) and is subsequently degraded by the ubiquitin-proteosome 
pathway. Conversely, in tumor cells, Wnt signaling, through the Frizzled serpentine 
receptor and the low-density lipoprotein receptor-related protein-5 or -6 (LRP5 or 6) 
coreceptors, activates the cytoplasmic phosphoprotein Dishevelled, which blocks the 
degradation of ǃ-catenin that accumulates in the cytosol and is translocated into the nuclei. 
Here, through the binding with transcription factors, T-cell factor (TCF)/lymphoid enhancer 
factor (LEF), ǃ-catenin activates transcription of genes such as cyclinD1 and c-MYC, thus 
modulating cell proliferation and invasion. 
Many of the molecular component of the WNT/-catenin signaling have been reported to 
be modified in HCC, and are proposed as HCC diagnostic/prognostic markers or as 
therapeutic target for treatment of the primary or metastatic malignancy (Table 4).  
Mutations of Axin or stabilizing mutations of -catenin genes, leading to constitutive 
activation of the Wnt/-catenin pathway, have been recovered in various cancers, including 
hepatoblastoma and HCC (Buendia, 2000; De La et al., 1998; Whittaker  et al., 2010). 
Conversely, inactivating mutations of the APC gene, frequently implicated in other tumor 
and particularly in colorectal cancer,  have not been described in HCC. However, loss of 
APC function activating the WNT/ǃ-catenin signaling seems to be implicated in liver 
carcinogenesis (Colnot et al., 2004). Moreover, aberrant reactivation of Wnt signaling due to 
accumulation of ǃ-catenin is evident in many different tumors of the liver (Colnot et al., 
2004). Frequent overexpression of the Wnt receptor Frizzled-7 has been detected in HCC 
and mainly in hepatitis B virus–related HCCs, and this overexpression seems to be an early 
event in hepatocarcinogenesis (Merle et al., 2004). It has been recently reported that serum ǃ-
catenin levels were significantly elevated in patients with HCC compared to those with 
chronic hepatitis or healthy controls, and it has been proposed as a potential marker for 
early diagnosis of HCC in HCV infected patients (Zekri et al., 2011). Moreover, in human 
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HCC tissues, higher levels of ǃ-catenin expression was found in the tumor area compared to 
the non-tumor area and the level of expression and nuclear translocation of ǃ-catenin was 
increased in HCC late-stage. Thus, ǃ-catenin have been proposed as a suitable diagnostic 
marker of metastasis in human HCC (Lai et al., 2011). 
 
Fig. 6. Schematic representation of the Wnt/ǃ-catenin signaling activation. APC, 
adenomatous polyposis coli; ǃ-cat, ǃ-catenin; CBP, CREB-binding protein; CK, casein kinase; 
DKK, Dickkopf; DSH, Dishevelled; GBP, GSK3-binding protein; GSK-3ǃ, glycogen synthase 
kinase 3ǃ; LRP, LDL receptor-related protein; P, phosphorylation; sFRP, secreted Frizzled-
related protein; TCF, T-cell factor. 
Finally, due to the tight interaction of ǃ-catenin with E-cad at the cell-cell junction, activation 
of WNT signaling has  also been related to dysregulation of cadherin expression, which is 
often associated with dysplasia, tumor formation, and metastasis. This causal relationship 
between E-cad and Wnt signaling makes E-cad an additional molecular marker that should 
be taken into account in the setting up a multiparametric diagnostic/prognostic platform for 
HCC. The E-cad expression levels have been reported to inversely correlate with histological 
grade and prognosis, and might be a prognostic marker of early recurrence of HCC after 
hepatic resection (Huang et al. 1999; Matsumura et al. 2001). Since E-cad expression is 
higher in well-differentiated tumors compared to poorly differentiated cancers, that exhibit 
lost of the intercellular junction integrity and development of metastasis (Shiozaki et al., 
1996; Wijnhoven et al., 2000), it may also be predictive of invasion and metastatization of 
HCC cells. 
While several drugs targeting the VEGF/VEGFR, PDGFR , EGF/EGFR and IGFR signaling 
have been approved or are in late-stage clinical trials (Fig. 5), clinically useful agents that 
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specifically inhibit Wnt signaling cascade are not currently available. However, owing the 
crucial role in cancer ascribed to this pathway, in the last years the researches on the 
molecular mechanisms driving this signaling are in increasing and conspicuous funds are 
invested by several pharmaceutical and biotech companies for the development of  
innovative drugs targeting its molecular components. The main therapeutic strategies 
currently explored include: 
1. The use of small-molecules able to regulate the catenin responsive transcription (Chen 
et al., 2009a; Lepourcelet et al., 2004; Thorne et al., 2010; Vo & Goodman, 2001). 
2. Compounds that inhibit Wnt signaling by influencing the stability and expression levels 
of ǃ-catenin (Chen et al., 2009a; Huang et al., 2009; Thorne et al., 2010) 
3. Molecules that inhibit Wnt signaling by acting on events upstream of the 
axin/APC/GSK-3ǃ complex, such as the secretion or reception of Wnt ligands at the 
plasma membrane (Chen et al., 2009a; Chen  et al., 2009b) or transduction of the Wnt 
signal by Dishevelled (Dvl) (Chen  et al., 2009b, Shan et al., 2005) 
 
Molecular 
component of 
the WNT 
signaling 
Biological 
material 
analyzed 
Trends found in HCC Main possible use/s 
ǃ-catenin Tissue Gene mutation recovered in 
pre-cancerous lesion and 
increased in tumor; increased 
mRNA expression compared to 
normal liver; nuclear 
translocation in the early stages; 
increased protein expression in 
the late stage
Indicative of WNT 
signaling activation 
(early diagnosis); 
diagnostic marker of 
metastasis ; 
therapeutic target 
ǃ-catenin Serum Elevated in patients with HCC
compared to those with chronic 
hepatitis (CH) and healthy 
controls
Early diagnosis of 
HCV-associated 
HCC 
APC Tissue Gene mutation not frequently 
evidenced; loss of function 
implicated  in liver 
carcinogenesis;
Early diagnosis; 
therapeutic target 
Frizzled receptor Tissue Overexpressed in HCC 
compared to normal liver, 
already at early stages
Early diagnosis; 
therapeutic target 
E-cadherin Tissue Expression increased in well-
differentiated tumors compared 
to poorly differentiated cancers; 
Expression levels inversely 
correlated with histological 
grade and prognosis 
Predictive of early 
recurrence after 
hepatic resection 
and metastatization 
of HCC cells; marker 
of tumor 
differentiation 
Table 4. List of the main molecular component of the WNT signaling useful for HCC 
diagnosis/therapy 
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Moreover, it has been recently reported that microRNA-181s (miR-181s) are transcriptionally 
activated by the Wnt/ǃ-catenin signaling in HCC and these miRs have been proposed as 
attractive molecular target to eradicate liver cancer stem cells (Ji et al., 2011)  
4. CD44 as a multifunctional marker of HCC late stages and metastatic 
disease, also useful for  targeted therapy and drug delivery 
The high mortality rate in patients with HCC is mainly due the lack of effective treatment 
options, especially for those with advanced or unresectable disease. These patients generally 
have a very poor prognosis and treatments, such as transarterial chemo-embolization, intra-
arterial or systemic chemotherapy, radiotherapy, immunotherapy or hormonal therapy, are 
mainly used as palliative. Thus, the development of more effective therapeutic tools and 
strategies is much needed. The conventional chemotherapy, implying the use of  systemic 
administration or non-targeted distribution of the drug, has numerous drawback such as the 
limited accessibility of drug to the tumor tissue, that reduces its therapeutic efficacy, the 
requirement of high doses, and undesirable side effects, primarily the high mielotoxicity and 
the development of multidrug resistance. To overcome these problems, in the last decades 
numerous researches focused on developing cancer-specific drugs or systems of antitumor 
drug delivery (Allen, 2002; Gabizon, 2002; Gabizon et al., 2003; Mohanty  et al., 2011; Sapra 
& Allen, 2003). This therapeutic strategy may allow a controlled release of the drug and a 
high targeting selectivity on tumor cells, increasing drug cytotoxicity and decreasing its 
undesirable side effects. In this context, targeted drug delivery involving the use of drugs 
covalently conjugated to macromolecular carriers, that are able to specifically link to over-
expressed molecules on tumor cells, is one the most promising approach in developing 
innovative therapies against cancer.  
CD44, the receptor for hyaluronic acid-mediated cell motility, is a highly glycosylated 
transmembrane protein involved in cell–cell and cell–matrix interactions. The standard 
isoform (CD44s), participates to several functions including lymphocyte homing, tissue 
regeneration, signal transmission involved in cell proliferation, migration and apoptosis 
(Goodison  et al., 1999; Ponta et al., 2003).  Besides its involvement in physiological activities 
of normal cells, CD44 is associated with pathologic functions of tumor cells. Increased 
expression of CD44 (the standard isoform CD44s and the splice variant CD44v) has been 
associated to advanced stages not only of hepatocellular carcinoma (Endo & Terada, 2000) 
but also of breast cancer, colorectal cancer, thyroid carcinoma, lung cancer, renal cell 
carcinoma, gallbladder carcinoma, ovarian carcinoma, endometrial cancer and melanoma 
(Akisik et al., 2002; Bendardaf et al., 2006; Jothy , 2003; Naor et al., 2002; Seiter et al., 1996). 
For this reason, CD44 is emerging as a valuable metastatic tumor marker, also associated 
with an unfavorable prognosis for a variety of cancers, including HCC (Beckebaum et al., 
2008). Therefore, agents specifically targeting CD44 should be promising drug for inhibiting 
tumor spread and for treatment of metastatic disease. It has been demonstrated that 
targeting CD44 with specific anti-CD44 monoclonal antibodies is able to inhibit proliferation 
and to induce terminal differentiation or apoptosis in leukemic cell lines (Charrad et al., 
2002; Jin et al., 2006). Furthermore, inhibition of CD44 expression by CD44 antisense 
oligonucleotide significantly induced apoptosis, decreased tumorigenesis and invasion, and 
increased chemosensitivity in a CD44 over-expressing human HCC cell line (Xie et al., 2008). 
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The described overexpression of CD44 in advanced stages of several kinds of cancer 
including HCC, makes hyaluronic acid (HA), the well-known component of the 
extracellular matrix to which CD44 binds for driving the cell motility, an excellent 
macromolecular carrier for anticancer drug delivery. HA is a natural and biodegradable 
polysaccharide formed by D-glucuronic acid and N-acetyl-D-glucosamine repetitive units 
(Fig. 7A), used for the development of pharmaceutical carriers and biomedical systems. HA 
plays crucial roles in cell adhesion, growth, and migration, by interacting with specific 
cellular receptors (CD44, RHAMM, ICAM), and acts as a signaling molecule in cell motility, 
inflammation, wound healing, and cancer metastasis (Marhaba & Zoller, 2004; Nedvetzkiet 
al., 2004; Toole, 2004; Weigel et al., 2003). In this context, HA-drug bioconjugates inherently 
show a marked selectivity for cancer cells, also providing advantages in drug solubilization, 
stabilization, localization, and controlled release. Bioconjugates of hyaluronic acid with 
different antineoplastic drugs, such as paclitaxel, doxorubicin and SN-38 (the active 
metabolite of  Irinotecan) have been reported to posses promising anti-tumor effects both in 
vitro  and in vivo (Banzato et al., 2008; Luo & Prestwich, 1999; Luo et al., 2000; Luo et al., 2002; 
Rosato et al., 2006; Serafino et al., 2011). 
 
Fig. 7. A: Molecular structure of hyaluronic acid. B: mechanism of HA-drug biocojugate 
internalization by cancer cells.  
In our recent paper (Serafino et al., 2011) we showed that the HA-drug bioconjugates, after 
interaction of the HA backbone with CD44, enter the tumor cells through a receptor-
mediated endocytosis, followed by release of the active drug in the cytosol, where it directly 
reach its site of action. The internalized bioconjugate/CD44 complex has been recovered on 
www.intechopen.com
 Hepatocellular Carcinoma – Basic Research 
 
90
cytoplasmic vesicles-like and lysosome-like structures, suggesting that processing of the 
HA-drug molecules might be coupled with a recycling of the CD44 receptor (Fig. 7B). We 
have also demonstrated that, using this drug delivery strategy, the delivered drug exerts a 
strong and irreversible in vitro inhibitory effect on growth of CD44 over-expressing cancer 
cells, higher than that exerted by free drug. 
As mentioned above, the effectiveness of the drug delivery strategy using HA as a carrier 
targeting its CD44 receptor has been demonstrated in several kinds of CD44 over-expressing 
tumors, including colorectal, ovarian, bladder,  gastric, breast, oesophageal and lung 
cancers, not only in vitro but also in vivo (Banzato et al., 2008; Luo & Prestwich, 1999; Luo et 
al., 2000; Luo et al., 2002; Rosato et al., 2006; Serafino et al., 2011). Due the association of 
increased expression of CD44 to advanced stages of hepatocellular carcinoma, this 
therapeutic approach might be also applicable for treatment of metastatic HCC. In addition, 
the growing evidences concerning the CD44 expression on liver cancer stem cells (Liu et al., 
2011) not only improve the prognostic significance of CD44 but also make the drug delivery 
strategy through CD44/HA binding interaction useful for eradicating hepatic cancer stem 
cells. 
5. Conclusion 
Hepatocellular carcinoma is a malignancy having multifactorial etiology and a very complex 
pathogenesis, that make difficult the clinical management of HCC patients. Similarly to the 
other kinds of cancer, HCC insurgence, progression and recurrence involve gene mutations, 
that might be different depending on the individual genotype profiling and tumor stage, 
and different signaling pathways, which often share some crucial molecules/steps and are 
subjected to additional post-transductional regulation. To overcome the complex network of 
signaling pathways and gene mutations underlying hepatic cancer, innovative diagnostic, 
prognostic and therapeutic strategies are needed. Nowadays, each existing biomarker used 
or proposed for HCC early diagnosis, staging and prognosis alone is poorly specific and the 
absolute positive and negative serological and/or immunohistochemical markers are still 
lacking. Even those markers selected for high sensitivity and specificity do not exhibit an 
universal diagnostic/prognostic value, also due to the individual genotype variability. The 
more promising approach for developing more specific diagnostic/prognostic tools might 
be to combine several positive or negative indicators in multiparametric platforms, that  
allow simultaneous detection of multiple serological or immunohistochemical markers for 
HCC. These platforms might be used to design “specific maps” for HCC early diagnosis, 
staging and prognosis, also taking into account the individual variability of each patient. 
Detecting expression patterns of combined biomarkers may also be a new method useful for 
identifying new and unique markers.  
Moreover, since target-specific cancer therapy has remarkably improved the outcomes of 
patients and represents the frontline approach for cancer treatment, the development of 
such multiparametric platforms would also represent a high-performance technological 
tools useful for designing personalized therapies, adapted to the aggressiveness of each 
individual tumor. The final goal should be to discriminate, for each target-specific therapy 
and on the basis of the “biomarker profiling” of each patient, the “responder” to the “not 
responder”, thus increasing the therapeutic effectiveness, improving patient outcomes, and 
resulting in saving healthcare costs. Thus, the discovery and validation of new HCC 
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biomarkers useful for early diagnosis and prognosis, such as the NGF, and for target 
therapy and drug delivery, such as the CD44, as well as the deepening of knowledge on 
pathways actively involved in hepatocarcinogenesis, helpful for HCC staging and target-
specific cancer therapy, such as the WNT/ǃ-catenin signaling, are essential steps to achieve 
this goal. 
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